Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Engelfriet

Showing results (131-140 of 165) with videos related to

Pageof 17
Sort By:
Vox Sanguinis|September 12, 2007
Donor recruitment researchD Devine, M Goldman, C P Engelfriet, et al.
Lancet (London, England)|September 17, 1988
What is the best predictor of the severity of ABO-haemolytic disease of the newborn?H A Brouwers, M A Overbeeke, I van Ertbruggen, et al.
Tissue Antigens|April 1, 1976
The search for standard HLA reagentsE Albert, E S Curtoni, J Dausset, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
Vox Sanguinis|August 24, 1999
The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-DC P Engelfriet, H W Reesink, J Bussel, et al.
British Journal of Haematology|September 1, 1980
Quantitative aspects of the destruction of red cells sensitized with IgG1 autoantibodies: an application of flow cytofluorometryF W van der Meulen, H G de Bruin, P C Goosen, et al.
Vox Sanguinis|March 24, 2000
Bacterial contamination of blood componentsC P Engelfriet, H W Reesink, M A Blajchman, et al.
Vox Sanguinis|January 5, 1999
The official requirements for platelet concentratesC P Engelfriet, H W Reesink, E L Snyder, et al.
Vox Sanguinis|March 1, 2003
Prenatal management of alloimmune thrombocytopenia of the fetusC P Engelfriet, H W Reesink, Hartmut Kroll, et al.
Vox Sanguinis|October 24, 1998
Use of cord blood progenitor cells as an alternative for bone marrow transplantationC P Engelfriet, H W Reesink, J E Wagner, et al.
Pageof 17

Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Vox Sanguinis|September 12, 2007
Donor recruitment researchD Devine, M Goldman, C P Engelfriet, et al.
Lancet (London, England)|September 17, 1988
What is the best predictor of the severity of ABO-haemolytic disease of the newborn?H A Brouwers, M A Overbeeke, I van Ertbruggen, et al.
Tissue Antigens|April 1, 1976
The search for standard HLA reagentsE Albert, E S Curtoni, J Dausset, et al.
Vox Sanguinis|September 2, 2000
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodiesC P Engelfriet, H W Reesink, P M Mannucci, et al.
Vox Sanguinis|August 24, 1999
The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-DC P Engelfriet, H W Reesink, J Bussel, et al.
British Journal of Haematology|September 1, 1980
Quantitative aspects of the destruction of red cells sensitized with IgG1 autoantibodies: an application of flow cytofluorometryF W van der Meulen, H G de Bruin, P C Goosen, et al.
Vox Sanguinis|March 24, 2000
Bacterial contamination of blood componentsC P Engelfriet, H W Reesink, M A Blajchman, et al.
Vox Sanguinis|January 5, 1999
The official requirements for platelet concentratesC P Engelfriet, H W Reesink, E L Snyder, et al.
Vox Sanguinis|March 1, 2003
Prenatal management of alloimmune thrombocytopenia of the fetusC P Engelfriet, H W Reesink, Hartmut Kroll, et al.
Vox Sanguinis|October 24, 1998
Use of cord blood progenitor cells as an alternative for bone marrow transplantationC P Engelfriet, H W Reesink, J E Wagner, et al.
Pageof 17